Jamie Stobo

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma

Philip Smith, Thomas Bradley, Lena Morrill Gavarró et al. · Nature Communications · 2023 · 59 citations · Full text

Medicine, Genetics, Oncology +17

Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.

Anthony J. Chalmers, Susan Short, Colin Watts et al. · Journal of Clinical Oncology · 2018 · 36 citations

Medicine, Oncology, Pharmacology +17

Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial

Sarah Derby, Mark R. Jackson, Karin Williams et al. · International Journal of Radiation Oncology*Biology*Physics · 2024 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).

T.R. Jeffry Evans, Bristi Basu, Richard Hubner et al. · Journal of Clinical Oncology · 2023 · 18 citations

Medicine, Oncology, Pharmacology +17

Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial

Emma D Johnson, Merete Long, Lídia Perea et al. · American Journal of Respiratory and Critical Care Medicine · 2025 · 18 citations

Medicine, Immunology, Pharmacology +17